Product image of Igantibe (Human Hepatitis B Immunoglobulin) supplied by GNH India

Igantibe

Active Ingredient:
Human Hepatitis B Immunoglobulin
Origin:
EU

Igantibe (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin, the active ingredient in Igantibe, is an immunoglobulin presented as an injectable solution for intramuscular use. It provides passive immunity to prevent hepatitis B infection after exposure and to protect newborns of HBsAg‑positive mothers.

GNH India supplies Igantibe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution, including cold‑chain logistics for biologic products and timely delivery.

Manufacturer / TM Owner

Instituto Grifols, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Igantibe, a hepatitis B immune globulin, is used within the hepatitis B prevention pathway.

  • Post‑exposure prophylaxis: Provides immediate passive immunity to reduce the risk of hepatitis B infection after known exposure.
  • Newborn protection: Prevents vertical transmission of hepatitis B from HBsAg‑positive mothers to their infants.
  • Liver transplant prophylaxis: Helps prevent recurrent hepatitis B infection in recipients of liver transplants from infected donors.
  • Chronic HBV carrier management: Offers short‑term protection for chronic carriers undergoing invasive procedures.

How It Works

  • Human Hepatitis B Immunoglobulin supplies high‑titer anti‑HBs antibodies that bind to hepatitis B surface antigen. By neutralizing circulating virus particles, the antibodies block viral entry into hepatocytes and facilitate clearance by the reticuloendothelial system. This passive immunization provides immediate protection while the host’s active immune response develops, thereby reducing the likelihood of infection establishment. The administered immunoglobulin remains active in the bloodstream for several weeks, extending the window of protection.

Side Effects

Igantibe may cause adverse reactions ranging from mild to severe.

Common Side Effects

  • Injection site pain: Local soreness or tenderness at the injection site.
  • Fever: Temporary rise in body temperature after the dose.
  • Headache: Mild to moderate headache reported by some patients.

Serious or Rare Side Effects

  • Anaphylaxis: Severe allergic reaction that may cause airway obstruction and shock.
  • Serum sickness: Rash, joint pain, and fever due to immune complex formation.
  • Hemolysis: Red blood cell destruction that can lead to anemia and jaundice.

Precautions & Warnings

Before using Igantibe, several precautions should be observed to ensure safety and efficacy.

  • Screen for HBV status: Verify that the patient is HBsAg‑negative before prophylactic use.
  • Assess hypersensitivity: Do not administer to individuals with known allergy to human immunoglobulins.
  • Monitor after injection: Observe the patient for at least 30 minutes for any immediate adverse reactions.
  • Evaluate pregnancy risk: Use only when the potential benefit justifies the potential risk to the fetus.
  • Avoid concurrent live vaccines: Delay live‑attenuated vaccinations for at least four weeks after administration.
  • Store at 2-8°C: Keep refrigerated, protect from light, and do not freeze or shake the product.

Avoid Interactions

Igantibe can interact with certain medicines or vaccines, requiring careful management.

Major Interactions (Avoid)

  • Live attenuated vaccines: Co‑administration may reduce vaccine efficacy and increase risk of adverse events.
  • Immunosuppressive therapy: Concurrent high‑dose steroids or biologics may diminish the protective effect of the immunoglobulin.

Moderate Interactions (Monitor Closely)

  • Blood products containing anti‑HBs: May lead to immune complex formation and increase risk of serum sickness.
  • Anticoagulants: Intramuscular injection can raise the chance of local hematoma; monitor coagulation status.
  • Renal‑impairing drugs: May exacerbate rare renal side effects; assess kidney function regularly.

Frequently Asked Questions

Igantibe is a hepatitis B immune globulin indicated for post‑exposure prophylaxis of hepatitis B infection, for preventing mother‑to‑child transmission in newborns of HBsAg‑positive mothers, and for protecting liver‑transplant recipients against recurrent hepatitis B infection.

The product delivers high‑titer anti‑HBs antibodies that bind to hepatitis B surface antigen, neutralising the virus and blocking its entry into liver cells. This passive immunity provides immediate protection while the patient’s own immune system develops a longer‑term response.

The dose of Igantibe is determined by the prescribing clinician based on the patient’s age, weight, exposure risk and clinical situation. Healthcare professionals follow local guidelines and product labeling to calculate the appropriate amount.

Safety data in pregnancy and lactation are limited. Igantibe should be used only when the expected benefit to the mother or fetus outweighs any potential risk. Clinicians should discuss individual circumstances with the patient and consider alternative options if appropriate.

To request Igantibe, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and the necessary import documentation.

Igantibe provides passive immunity through anti‑HBs antibodies, offering immediate protection, whereas hepatitis B vaccines stimulate active immunity over weeks. In situations requiring rapid protection—such as after accidental exposure or in newborns of infected mothers—Igantibe is preferred, often in combination with vaccination for long‑term immunity.

Igantibe must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration.

Igantibe is given by intramuscular injection, typically into the deltoid or gluteal muscle. The administration site should be rotated when multiple doses are required, and patients should be observed for a short period after injection for any immediate reactions.

The most serious adverse events include anaphylactic reactions, serum sickness, and hemolysis. Patients should be monitored closely after injection, and any signs of severe allergic response—such as difficulty breathing, swelling, or hypotension—require immediate medical attention.

Igantibe is contraindicated in individuals with a known hypersensitivity to human immunoglobulin products. It should also be avoided in patients who have received a live‑attenuated vaccine within the previous four weeks, unless the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Hepatitis B Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT